What Viadil Compuesto Treats: Main Uses and Benefits

The active components are used in conditions presenting with acute episodes of pain.

Viadil Compuesto is applied in situations involving certain distressing symptoms of severe pain that is directly caused by painful smooth muscle spasms within internal organs. The primary therapeutic purpose is to offer supportive symptomatic relief by targeting the symptom clusters of pain and spasm, which helps patients cope more steadily with difficult acute episodes. This medication is commonly used for episodic manifestations like renal colic and biliary colic, as well as intestinal colic and spasmodic colitis.

“The therapeutic goal is to address acute symptomatic episodes that involve pronounced discomfort and heightened physiological activity.”

The medication is also relevant in contexts marked by increased discomfort or tension, such as managing dysmenorrhea (severe menstrual cramps) or post-operative pain that includes a spasmodic component. Additionally, it is relevant for easing the symptoms of high fever that may accompany these acute, painful conditions. This supportive strategy contributes to improved comfort during periods of heightened symptoms. These components are used for the management of colic-type pain and high fever, which may be part of symptomatic management.

---

Quick Fact: Supports management of Severe Visceral Cramping

---

Regulatory References

1. official drug labeling supported by the Spanish Agency of Medicines and Medical Products (AEMPS)

Eligibility for Viadil Compuesto: Official Regulatory Status

Official regulatory documents define strict criteria for using Viadil Compuesto (Pargeverine hydrochloride/Sodium Metamizole), focusing heavily on the safety profile of the Metamizole component.

Populations For Whom Use is Contraindicated

Use is absolutely prohibited for individuals with a known hypersensitivity to any component or other pyrazolone derivatives. It is also contraindicated in patients with a history of agranulocytosis induced by Metamizole, impaired bone marrow function, Acute Hepatic Porphyria, or G6PD deficiency. The medicine must not be used during the third trimester of pregnancy and is contraindicated for infants below three months of age or weighing less than 5 kg.

Age and Conditional Use Restrictions

Adults (ge 18 years) and adolescents ge 15 years are the standard eligible groups. Use in children under 15 years for the fixed-dose combination is generally not recommended. The medicine is not recommended during the first and second trimesters of pregnancy or while breastfeeding, requiring a 48-hour cessation period after a single dose. Use requires caution and often dose reduction in patients with existing hepatic impairment (liver problems) or renal impairment (kidney problems).

Interactions with Other Medicines and Products

The interaction profile of Viadil Compuesto, which contains Sodium Metamizole and Pargeverine hydrochloride, is primarily governed by the metabolic activity of Metamizole. Regulatory documents confirm that Metamizole is a documented moderate inducer of hepatic enzymes CYP3A4, CYP2B6, and CYP2C19. It is also classified as a weak inhibitor of CYP1A2. This enzyme induction results in pharmacokinetic interactions that accelerate the clearance of co-administered drugs.

This metabolic activity officially leads to a decreased exposure for medicines that are substrates of these enzymes. Specifically, the regulatory documentation notes that co-administration reduces the serum levels of Ciclosporin and may decrease the plasma concentration of Tacrolimus and Efavirenz. For these drugs, the interaction creates a context constraint where reduced exposure must be considered.

Pharmacodynamic interactions are also officially documented. Co-administration of Metamizole and low-dose Aspirin (for cardioprotection) is noted to inhibit the antiplatelet effect of aspirin. To mitigate this effect, regulatory sources require separation of dosing times. An additive risk of haematologic toxicity is noted when combined with Methotrexate, and a risk of additive hypothermia exists with Chlorpromazine. Furthermore, the Pargeverine component presents an interaction restriction: co-administration with alcohol may cause an exacerbation of documented central nervous system effects, such as increased drowsiness.

Modulation of Peripheral Smooth Muscle Contraction and Central Signaling

Viadil Compuesto acts through two primary, complementary mechanistic domains: modulation of peripheral smooth muscle contraction and modulation of central pain and temperature pathways. This parallel action modulates both visceral motor activity and central nociceptive signaling by engaging separate biological systems.

Pargeverine: Visceral Motor Activity Modulation

The Pargeverine component exerts its action primarily in the periphery. It works as an antagonist on muscarinic receptors and blocks L-type voltage-gated calcium channels on visceral smooth muscle cells in the gastrointestinal, biliary, and genitourinary tracts. This dual blockade reduces the excitatory input and limits the calcium influx necessary for muscle shortening, resulting in the reduction of visceral smooth muscle contraction and decreased tone.

Paracetamol: Central Pain and Temperature Pathway Adjustment

The Paracetamol component acts mainly in the Central Nervous System (CNS). Its central effect is linked to the weak inhibition of CNS Cyclooxygenase (COX) enzymes, which reduces the synthesis of Prostaglandin E2 ( PGE2). Furthermore, the activity of its metabolite on TRPV1 and CB1 receptors helps to modulate central pain processing. The resulting physiological consequence is the attenuation of central nociceptive signal transmission and the resetting of the hypothalamic thermoregulatory set-point.

Instruction Map: How to use Viadil Compuesto — administration guidelines

Viadil Compuesto (Pargeverine hydrochloride and Sodium Metamizole) is administered according to specific requirements and dosing schedules. The medicine is supplied in Oral Tablets (Grageas), Oral Drops, and a two-ampoule Injectable Solution, allowing for oral, intramuscular (IM), and slow intravenous (IV) administration.

---

Administration Scope

Property	Instruction
Route of administration	Oral, Intramuscular (IM), and Intravenous (IV).
Dosing schedule	Adults Oral: 1 to 2 tablets or 20 to 40 drops per dose. Adults Injectable: 1 combined dose per administration.
Frequency and timing	Administered 3 to 5 times per day for oral forms, or 1 to 4 times per day for the injectable solution.
Preparation requirements	The injectable dose requires the mixing of the entire contents of both Ampoule I and Ampoule II into a single syringe before use.
Age-group rules	Pediatric Oral Drops (2 -12 years): Dosing is based on age, using 2 drops per year of age per administration.
Special conditions	The IV administration must be performed as a slow injection. Use is intended for acute episodes, consistent with short-term, as-needed dosing.

---

Resulting Procedural Structure

Step sequence:

• Oral Intake: Consume the prescribed tablet or drop dose with water.
• Parenteral Preparation: Combine the full contents of both ampoules into one syringe.
• Parenteral Administration: Administer the mixed solution via the IM route or via slow IV injection.

The use protocol is structured to deliver the medicine through oral or parenteral routes, with administration frequency defined by maximum daily limits. Critical procedural steps, such as the required mixing of the two ampoules and the condition of slow IV injection, are elements that dictate the medicine's intended usage.

Research Evidence / Overview of Studies for Viadil Compuesto

Evidence for use in Acute Visceral Spasmodic Pain

Research explored the active components’ role in conditions associated with acute visceral spasm, such as renal colic. These studies involved short-term randomized controlled trials (RCTs) and systematic reviews that examined the combination's components in research exploring short-term symptom changes. The populations studied were mainly adult patients presenting with episodic or acute changes.

Studies monitored patient-reported outcomes describing perceived discomfort by tracking changes in symptom intensity and examining whether patients reported changes that reached a specific threshold within a few hours. Findings describe patterns observed in the studies that were usually restricted to the acute, short-term treatment window, where follow-up durations were short. Research examined the role of the spasmolytic component (Pargeverine hydrochloride) in outcomes related to physical discomfort in specific conditions, such as renal colic, and findings were mixed.

Because the product is a fixed-dose combination, data show patterns related to limitations in the current evidence. Research highlights changes measured during the study period, but comparative evidence is lacking to show the fixed-dose approach provides clear comparative outcomes over using the components separately.

---

Evidence for Antipyretic Use in Acute Fever

Research for the analgesic component was studied for outcomes related to systemic or functional imbalance, and the evidence level is graded as high. Studies focusing on episodes where symptoms become more noticeable included systematic reviews and meta-analyses of many randomized controlled trials. These trials monitored outcomes related to systemic or functional imbalance by measuring changes in core body temperature.

Research explored short-term symptom changes in both febrile children and adults. Studies monitored how symptoms evolved in the observed populations following a single dose. Research reported how symptoms evolved in the observed populations, and the measured outcomes were similar to those reported for other common non-opioid fever medications.

---

What Research Gaps and Uncertainty Remain

The available evidence highlights what is known—and what is still uncertain—about this fixed-dose combination. The main uncertainty centers on the fixed-dose approach itself, as regulatory bodies note a need for more research that clearly establishes the comparative outcomes of the two components being pre-combined versus being used as separate treatments.

Additionally, long-term effects are not fully established because follow-up durations were limited across the primary studies. Subgroup findings are uncertain for several populations (e.g., older adults, infants, specific comorbid groups) because the results apply only to the narrowly defined populations studied in the clinical programs.

Key Studies & References

1. Technical Summary Sheet (Ficha Técnica) for a Metamizol-containing product (AEMPS Ref. 85080)

Common questions about Viadil Compuesto (FAQ)

Q: What is Viadil Compuesto used for?

Viadil Compuesto is a combination medicine used to treat spasms (cramping or tightness) and associated pain in the digestive tract, biliary tract (gallbladder and bile ducts), and genitourinary tract (urinary bladder, urethra, and kidneys). It is commonly prescribed for conditions such as irritable bowel syndrome, biliary colic (gallstone pain), kidney colic (kidney stone pain), and painful menstrual cramps.

---

Q: How does Viadil Compuesto work?

Viadil Compuesto contains two active ingredients: Proxifilina and Metamizole (also known as Dipyrone).

• Proxifilina is an antispasmodic agent. It works by relaxing the smooth muscles in the walls of the affected organs (like the intestine, bile ducts, and ureters), which relieves the painful spasms.
• Metamizole is a powerful analgesic (pain reliever) and antipyretic (fever reducer). It acts on the central nervous system to reduce the perception of pain, complementing the antispasmodic action of Proxifilina.

Together, these components address both the muscle cramping and the resulting pain.

---

Q: Who should not take Viadil Compuesto?

Viadil Compuesto is contraindicated (should not be taken) by individuals with:

• A known allergy or hypersensitivity to Proxifilina, Metamizole (Dipyrone), other pyrazolones (like Phenylbutazone), or any of the inactive ingredients.
• Certain blood disorders, such as agranulocytosis (a severe drop in white blood cells) or severe bone marrow dysfunction.
• Acute intermittent porphyria (a genetic metabolic disorder).
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency (a genetic condition).
• Severe liver or kidney impairment.
• Pregnancy, particularly during the first and last trimesters, and while breastfeeding.

Always inform your healthcare provider about your complete medical history before starting this medication.

---

Q: What are the potential side effects of Viadil Compuesto?

Like all medicines, Viadil Compuesto can cause side effects, although not everyone experiences them. The most serious, though rare, potential side effect associated with Metamizole is agranulocytosis, which is a severe and potentially life-threatening reduction in white blood cells. Signs of this can include a sudden onset of fever, chills, sore throat, or mouth ulcers. Seek immediate medical attention if these symptoms occur.

Common or less severe side effects may include:

• Gastrointestinal issues such as dry mouth, nausea, or vomiting.
• Dizziness or drowsiness.
• Allergic skin reactions, such as rash or itching.
• A harmless red discoloration of the urine (due to a metabolite of Metamizole).

If you experience any concerning side effects, consult your healthcare provider.

---

Q: Can Viadil Compuesto interact with other medications?

Yes, Viadil Compuesto can interact with several other medications, primarily due to the Metamizole component. Inform your doctor or pharmacist if you are taking any of the following, as they may require dose adjustments or a change in treatment:

• Cyclosporine (used to prevent organ rejection or for autoimmune diseases), as Metamizole can reduce its blood levels.
• Methotrexate (used for cancer and autoimmune diseases), as this combination may increase the risk of blood toxicity.
• Chlorpromazine (an antipsychotic), as this combination may increase the risk of hypothermia.
• Aspirin (Acetylsalicylic Acid), as Metamizole may reduce its antiplatelet effect.
• Other non-steroidal anti-inflammatory drugs (NSAIDs) or pain relievers.

This is not a complete list. Always provide a full list of all prescription and non-prescription medications, herbal supplements, and vitamins you are taking to your healthcare provider.

How to Store and Dispose of Viadil Compuesto?

Official regulatory guidelines define strict conditions for the storage and disposal of Viadil Compuesto to maintain its stability and ensure safety.

Mandatory Storage Requirements

Condition	Requirement
Temperature	Store below 30 C, or below 25 C for certain forms, in an ambient environment.
Protection	Keep the product protected from light and in a dry place.
Container	Must be kept in the original container/package to preserve integrity.
Child Safety	Mandatory rule to keep out of the sight and reach of children.

️ Official Disposal Guidance

Unused or expired medication must be handled according to local pharmaceutical waste disposal regulations or through approved drug take-back programs. To prevent environmental exposure to the active components, the product must not be discarded in household wastewater (e.g., flushed down the toilet or poured down a sink).